Government of Business, By Business, For Business - Part I - Page 2

Hinchey has learned that in at least four separate cases, Troy's Chief Counsel office has submitted briefs arguing the side of the defendant corporation against the families of people who died after using that corporation's product. In three of those cases, Hinchey found evidence of inappropriate collusion or conflict of interest between Troy and the companies the counsel's office stood up for.

In one case (Motus v. Pfizer), Troy was advocating on behalf of Pfizer, which had paid $360,000 for Troy's legal services the year he accepted the FDA post. In another (Murphree v. Pacesetter), evidence shows that the defendant's lawyer was directing the FDA on how best to intervene. In the third (Dowhal v. SmithKline Beecham Consumer Healthcare), Troy met personally with the defendant's lawyer before filing the brief. In none of the four cases did the court request an opinion from the FDA. This unsolicited insinuation into state civil suits represents a radical departure from the FDA's established practices, a fact Troy and the FDA have tried to obscure.

Currently, Daniel Troy is listed as "Associate General Counsel" so it appears the administration solved the problem by hiding him under a cabbage leaf to make him less visible.

What a country.

Write your Senators and House Representative if you'd like it to be a better place. It shouldn't be a partisan issue.

Further reading:

The Myth of High Drug Research Costs

Article Author: Hal Pawluk

Visit Hal Pawluk's author page — Hal Pawluk's Blog